Parkin Edward, O'Reilly Derek A, Sherlock David J, Manoharan Prakash, Renehan Andrew G
Institute of Cancer Sciences, University of Manchester, Manchester, UK; Department of Hepatobiliary Surgery, North Manchester General Hospital, Manchester, UK.
Obes Rev. 2014 May;15(5):434-51. doi: 10.1111/obr.12140. Epub 2014 Jan 17.
Excess adiposity is an established risk factor for incident colorectal cancer (CRC) but whether this association extrapolates to poorer survival is unclear. We undertook a systematic review to examine relationships between measures of adiposity and survival in patients with CRC. For distinction, we included pre-diagnosis exposure and CRC-related mortality. We performed dose-response meta-analyses and assessed study quality using eight domains of bias. Six study categories were identified based on (i) timing of adiposity measurement relative to survival analysis time zero and (ii) clinical setting. Several types of adiposity measurements were reported; body mass index (BMI) was the commonest. For pre-diagnosis cohorts, baseline BMI negatively impacted on CRC-related mortality in men only (risk estimate per 5 kg m(-2) = 1.19, 95% confidence intervals: 1.14-1.25). The other groups were pre-diagnosis BMI but diagnosis as time zero; population-based cohorts; treatment cohorts; observational analyses within adjuvant chemotherapy trials; patients with metastatic CRC - each had several biases (e.g. treatment selection, reverse causality) and sources of confounding (e.g. chemotherapy 'capping'). Overall, there was insufficient evidence for a strong link between adiposity and survival. These findings demonstrate an important principle: an established link between an exposure (here, adiposity) and increased cancer incidence does not necessarily extrapolate into an inferior post-treatment outcome.
肥胖是结直肠癌(CRC)发病的既定风险因素,但这种关联是否会导致较差的生存率尚不清楚。我们进行了一项系统综述,以研究肥胖指标与CRC患者生存率之间的关系。为了加以区分,我们纳入了诊断前暴露情况和与CRC相关的死亡率。我们进行了剂量反应荟萃分析,并使用八个偏倚领域评估研究质量。根据(i)肥胖测量时间相对于生存分析时间零点以及(ii)临床环境,确定了六个研究类别。报告了几种类型的肥胖测量方法;体重指数(BMI)是最常见的。对于诊断前队列,仅男性的基线BMI对与CRC相关的死亡率有负面影响(每5 kg m(-2)的风险估计值 = 1.19,95%置信区间:1.14 - 1.25)。其他组包括诊断前BMI但以诊断为时间零点;基于人群的队列;治疗队列;辅助化疗试验中的观察性分析;转移性CRC患者 - 每组都存在多种偏倚(如治疗选择、反向因果关系)和混杂因素来源(如化疗“封顶”)。总体而言,没有足够的证据表明肥胖与生存率之间存在紧密联系。这些发现证明了一个重要原则:暴露因素(此处为肥胖)与癌症发病率增加之间已确立的联系不一定会延伸至较差的治疗后结局。